GlassScriptPhysician profile
Christopher Myers
NPI 1417979618
$769.57
in general payments reported to CMS, 2019-2025
17 companies · $52.83 in 2025
The $52.83 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.79 · 2022: $44.03 · 2023: $112 · 2024: $534 · 2025: $52.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $698.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $119.27 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $105.01 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $84.07 | 2021-2024 | Veozah |
| Novo Nordisk INC | $79.73 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $74.43 | 2024 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $51.30 | 2024 | Trintellix |
| Phathom Pharmaceuticals, INC. | $38.50 | 2024 | Voquezna |
| Tactile Systems Technology INC | $36.74 | 2025 | Flexitouch Plus, Nimbl |
| Abbvie INC. | $34.89 | 2024-2025 | |
| Sanofi Pasteur INC. | $22.16 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.32 | 2023 | |
| Pfizer INC. | $20.19 | 2023 | |
| Glaxosmithkline, LLC. | $18.63 | 2024 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.34 | 2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $16.88 | 2024 | Vaxneuvance, Gardasil 9, Capvaxive |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.57 | 2024 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $13.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Myers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.